Icos COPD agent fails Phase II
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Failure of Icos' IC485 in a Phase II chronic obstructive pulmonary disease study is shifting the firm's focus to its "preclinical-stage PDE-4 inhibitors that are more potent and have other characteristics that enhance the probability of clinical success." The clinical-stage PDE-4 inhibitor did not meet the primary endpoint of improved lung function in a 258-patient placebo-controlled study, Icos says March 23...